No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
The quest to improve vaccination efforts in developing nations may yield huge side benefits to the industrialized world; an end to needle injections.
AZN reportedly goes ex-dividend next week. I believe the date is 8/9.
Up almost 1% in pre-market. Looks like buyers are coming back and paying up. Any speculation of a possible deal will make this baby pop, and that appears to be behind the buying interest.
Looks like $30 is the new base. Once speculation starts about who might have an interest in buying AZN, I expect the stock will move up a couple of bucks. The upcoming generous dividend makes it easy to hold and wait, especially if you bought on the recent drop.
AZN's drop has made it more attractive as a buyout play. Next week's dividend is another positive reason to be buying in here. Just saw an article saying PFE's less than stellar earnings show a need to do a deal. If not PFE, could be another large pharma come a knockin'.
It will go up
AZN should give us a bit of a pop today.
Hey Hey Hey
For as much as I want a buyout, I don't think it will happen with Soriot and the current board. Soriot has to go before he destroys anymore shareholder value. The media has to stop to referring to the PFE offer #$%$ GBP/share, that minimizes the damage Soriot has already inflicted on the shareholders including that homer Woodford. The PFE offer was $116-$120 Billion. Soriot cost the shareholders $45+ Billion dollars. None of the promises from his forked tongue will come to fruition. All we can hope for is if an activist shareholder can force the company to put itself up for sale.. I can't believe any of the large shareholders can just sit passively as Soriot continues to sell off the family jewels to hit his bonus.
Benralizumab has an FDA action date during Q4 2017 and AstraZeneca are preparing to launch in the US in the beginning of 2018 .
I bought some AZN because they make great meds. So thankful.
up to 34
AH traded @$31.5, was it for real?
Hey Hey Hey
I expect Soriot to leave for Teva now that the bad news is out since he can't be accused of acting on non-public info anymore. If the board has any sense of fairness to the shareholders, this company should be put up for sale.
The PFE guys must be happy that they did not make a huge mistake buying AZN.
KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.